共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
3.
4.
5.
Oral lichenoid reactions associated with anti‐PD‐1/PD‐L1 therapies: clinicopathological findings 下载免费PDF全文
V. Sibaud C. Eid V.R. Belum P. Combemale B. Barres L. Lamant L. Mourey C. Gomez‐Roca C.L. Estilo R. Motzer E. Vigarios M.E. Lacouture 《Journal of the European Academy of Dermatology and Venereology》2017,31(10):e464-e469
6.
7.
8.
9.
10.
J. Bonigen C. Raynaud‐Donzel J. Hureaux N. Kramkimel A. Blom G. Jeudy A.‐L. Breton T. Hubiche C. Bedane D. Legoupil A. Pham‐Ledard J. Charles M. Pérol E. Gérard P. Combemale D. Bonnet M.‐L. Sigal E. Mahé the Groupe de Recherche sur le Psoriasis the Groupe Cancérologie Cutanée of the Société Française de Dermatologie the GEM Resopso Apsoderm the Groupe Français de Pneumo‐Cancérologie 《Journal of the European Academy of Dermatology and Venereology》2017,31(5):e254-e257
11.
12.
Iakov Shimanovich Christian Rose Yoshiaki Hirako Elke Butt‐Drje Detlef Zillikens 《Journal der Deutschen Dermatologischen Gesellschaft》2004,2(1):7-14
Anti‐p200 pemphigoid is an autoimmune skin disease characterized by tense blisters, subepidermal split formation, and mainly neutrophilic inflammatory infiltration of the dermal‐epidermal junction (DEJ). Direct immunofluorescence microscopy of perilesional skin biopsies demonstrates linear deposits of IgG and C3 along the DEJ, while by indirect immunofluorescence microscopy on NaCl‐split human skin, patients' IgG labels the dermal side. The antigenic target of the autoantibodies is a 200 kD protein (p200) of the lower lamina lucida that can be detected in human dermal extracts by immunoblotting. While p200 is thought to be important for cell‐matrix adhesion, its exact identity is unknown. To date, the p200 autoantigen has been demonstrated to be distinct from bullous pemphigoid antigens 180 und 230, laminin 1, 5, and 6, α6β4 integrin, and type VII collagen. Biochemical characterization of the p200 molecule revealed a noncollagenous N‐glycosylated acidic protein with an isoelectric point of approximately 5.5. We provide an overview on pathogenesis, clinical features, diagnosis, and treatment of this unique autoimmune dermatosis. 相似文献
13.
14.
15.
16.
17.
18.
Katharina C. Khler Jessica C. Hassel Lucie Heinzerling Carmen Loquai Kai‐Martin Thoms Selma Ugurel Lisa Zimmer Ralf Gutzmer 《Journal der Deutschen Dermatologischen Gesellschaft》2020,18(6):582-609
CTLA‐4 and PD‐1 play a key role in tumor‐induced downregulation of lymphocytic immune responses. Immune checkpoint inhibitors have been shown to alter the immune response to various cancer types. Anti‐CTLA‐4 and anti‐PD‐1 antibodies affect the interaction between tumor, antigen‐presenting cells and T lymphocytes. Clinical studies of the anti‐CTLA‐4 antibody ipilimumab and the anti‐PD‐1 antibodies nivolumab and pembrolizumab have provided evidence of their positive effects on overall survival in melanoma patients. Combined treatment using ipilimumab and nivolumab has been shown to achieve five‐year survival rates of 52 %. Such enhancement of the immune response is inevitably associated with adverse events. Knowledge of the spectrum of side effects is essential, both in terms of prevention and management. Adverse events include colitis, dermatitis, hypophysitis, thyroiditis, hepatitis and other, less common autoimmune phenomena. In recent years, considerable progress has been made in the detection and treatment of the aforementioned immune‐related adverse events. However, early diagnosis of rare neurological or cardiac side effects, which may be associated with increased mortality, frequently pose a challenge. The present update highlights our current understanding as well as new insights into the spectrum of side effects associated with checkpoint inhibitors and their management. 相似文献
19.
20.
Estelle Kahn M.D. Allyson Spence Shishido M.D. Kim B. Yancey M.D. Leslie P. Lawley M.D. 《Pediatric dermatology》2014,31(3):e76-e79
Mucous membrane pemphigoid (MMP), an autoimmune subepithelial blistering disease that predominantly affects the mucous membranes, is usually diagnosed in elderly adults. Early diagnosis of MMP is crucial because it tends to run a chronic and progressive course with the potential for devastating scarring of the mucous membranes that may lead to blindness and airway compromise. A subtype of MMP, anti‐laminin‐332 MMP, is a rare blistering disorder in which autoantibodies are directed against laminin‐332 (formerly epiligrin), a structural protein of the epidermal basement membrane. Herein we report what we believe to be the youngest patient diagnosed with anti‐laminin‐332 MMP, a 9‐year‐old girl with disease affecting only the oral, pharyngeal, and laryngeal mucosa, with no skin involvement. 相似文献